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Scale for Allergic Conjunctivitis
Disease
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ABSTRACT
Background: The objective of this study is to evaluate the practical usefulness of a scoring system using the
5-5-5 exacerbation grading scale for allergic conjunctivitis disease (ACD).
Methods: Subjects were 103 patients with ACD including 40 patients with vernal keratoconjunctivitis (VKC),
20 patients with atopic keratoconjunctivitis (AKC), and 43 patients with allergic conjunctivitis (AC).
The 5-5-5 exacerbation grading scale consists of the following 3 graded groups of clinical observations: the
100-point-grade group (100 points for each observation) includes active giant papillae, gelatinous infiltrates of
the limbus, exfoliative epithelial keratopathy, shield ulcer and papillary proliferation at lower palpebral conjunc-
tiva; the 10-point-grade group (10 points for each observation) includes blepharitis, papillary proliferation with
velvety appearance, Horner-Trantas spots, edema of bulbal conjunctiva, and superficial punctate keratopathy;
and the 1-point-grade group (1 point for each observation) includes papillae at upper palpebral conjunctiva, fol-
licular lesion at lower palpebral conjunctiva, hyperemia of palpebral conjunctiva, hyperemia of bulbal conjunc-
tiva, and lacrimal effusion. The total points in each grade group were determined as the severity score of the 5-
5-5 exacerbation grading scale.
Results: The median severity scores of the 5-5-5 exacerbation grading scale in VKC, AKC and AC were 243
(range: 12-444), 32.5 (11-344), and 13 (2-33), respectively. The severity score of each ACD disease type was
significantly different (P < 0.001, Kruskal-Wallis test). The severity of each type of ACD was classified as se-
vere, moderate, or mild according to the severity score.
Conclusions: The 5-5-5 exacerbation grading scale is a useful clinical tool for grading the severity of each
type of ACD.
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INTRODUCTION
Allergic conjunctivitis disease (ACD) is a conjunctival
inflammatory disorder caused by an immediate hy-
persensitivity response. ACD is divided into several
clinical types such as allergic conjunctivitis (AC),
atopic keratoconjunctivitis (AKC) and vernal kerato-
conjunctivitis (VKC).1 However, each clinical type of
ACD is different in severity and pathognomonic clini-
cal manifestations. They are influenced by genetic
elements and environmental factors such as season,
climate, and home environment. Therefore, in clinical
practice with ACD patients, an accurate diagnosis of
the severity of the disease is essential in selecting the
most effective therapy.
Converting clinical observations into clinical scores
is useful when evaluating the clinical severity of ACD
objectively. Results of epidemiological investigations
and measurement of the effects of therapeutic drugs
using clinical scores have been reported.2-7 The effec-
tive severity score may make it possible to objectively
determine the indication or cancellation stage for
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Table 1 Number and characteristics of the subjects
Sex
(Male : Female)
Age (Years)
(Mean ± SD)
No. of 
subjects
 : 2221 ± 17.025.743AC
 : 911 ± 12.424.520AKC
 : 634 ± 8.316.140VKC
AC, alergic conjunctivitis; AKC, atopic keratoconjunctivitis; 
VKC, vernal keratoconjunctivitis.
therapeutic drugs such as antiallergic drugs, im-
munosuppressive drugs, or corticosteroids. On the
other hand, when we treat patients with ACD, the use
of a clinical severity scoring system that reflects sub-
tle variations in the severity of ACD is helpful for our
practice. The scores for a clinical severity scoring sys-
tem should be simple and quick to judge, and sever-
ity scores should not be determined based on the in-
dividual differences of the observers. In addition, by
sharing the clinical severity score between the doc-
tor, patient and patient’s family, it can increase their
involvement in the planning for treatment. It may also
improve self-care of the patient.
We used the 5-5-5 exacerbation grading scale to
evaluate the clinical severity of patients with ACD.
The aim of our study was to evaluate the utility of this
scale.
METHODS
SUBJECTS
Subjects were 103 patients (103 eyes) with ACD who
visited the Department of Ophthalmology, Nihon
University Itabashi Hospital, between January 2004
and December 2007. For every patients with ACD, in-
formed consent for this study was obtained before en-
rollment. Patients with ACD were classified into 3
groups; 40 patients (40 eyes) with VKC, 20 patients
(20 eyes) with AKC, and 43 patients (43 eyes) with
AC. Demographic data are shown in Table 1. ACD
was diagnosed based on the following 3 criteria: (1)
having slit-lamp microscopic findings of ACD, (2) un-
dergone examination for allergen-specific IgE anti-
bodies in serum such as house-dust-mite or Japanese
cedar pollen by the AlaSTATⓇ (Mitsubishi Kagaku
Iatron, Tokyo, Japan) method, and identified to be
positive for some allergens, (3) patients with non-
allergic conjunctivitis, such as infectious conjunctivi-
tis, phlyctenular keratoconjunctivitis, superior limbic
keratoconjunctivitis, drug toxicity conjunctivitis, and
cicatricial conjunctivitis, were excluded from the
study.
Furthermore, ACD was classified into AC, VKC
and AKC according to the characteristics of the fol-
lowing clinical observations.8 AC is papillary conjunc-
tivitis, which is characterized by itching, burning,
redness, chemosis, and lid edema, but without prolif-
erative conjunctival lesions such as giant papillae of
the superior tarsal conjunctiva or gelatinous hypertro-
phy of the limbus. VKC is a recurrent and chronic
conjunctivitis with mucous discharge, characterized
by proliferative conjunctival lesion and keratopathy.
AKC is a chronic ocular surface disorder related to
atopic dermatitis and characteristics of AKC are re-
ported by Hogan9 and Foster.10
THE 5-5-5 EXACERBATION GRADING SCALE
The guidelines for evaluating the 5-5-5 exacerbation
grading scale are demonstrated in Table 2. The criti-
cal clinical observations of ACD were classified into
the 100-point-grade group, 10-point-grade group or 1-
point-grade group, according to the clinical severity
of ACD, and 5 critical findings were identified in each
grade group. Each positive observation in the 100-
point-grade group represented 100 points. Each posi-
tive observation in the 10-point-grade group repre-
sented 10 points, and each positive observation in the
1-point-grade group represented 1 point. When there
were no findings it was scored as 0 points. Finally,
the 5-5-5 exacerbation grading scale was determined
by the number of total points scored from clinical ob-
servations.
The 100-point-grade group was determined based
on the the presence of the following observations: ac-
tive giant papillae (Fig.1 A-1), gelatinous infiltrates of
the limbus (Fig.1 A-2), exfoliative corneal epitheliopa-
thy (Fig.1 A-3), shield ulcer (Fig.1 A-4), and papillary
proliferation at lower tarsal conjunctiva (Fig.1 A-5).
The guidelines for evaluation are shown in Figure 1.
The 10-point-grade group was determined based on
the presence of the following observations: blephari-
tis (Fig.2 B-1), papillary proliferation with velvety ap-
pearance (Fig.2 B-2), Horner-Trantas spot (Fig.2 B-
3), edema of bulbal conjunctiva (Fig.2 B-4), and su-
perficial punctate keratopathy (Fig.2 B-5). The guide-
lines for evaluation are shown in Figure 2. The 1-
point-grade group was determined based on the pres-
ence of the following observations: papillae at upper
tarsal conjunctiva (Fig.3 C-1), follicular lesion at
lower tarsal conjunctiva (Fig.3 C-2), hyperemia of tar-
sal conjunctiva (Fig.3 C-3), hyperemia of bulbal con-
junctiva (Fig.3 C-4), and lacrimal effusion (Fig.3 C-5).
The guidelines for evaluation are shown in Figure 3.
Furthermore, the severity classes of each group were
divided into mild, moderate or severe, according to
the criteria shown in Table 3.
RESULTS
Results using the 5-5-5 exacerbation grading scale in
patients with AC, AKC and VKC are shown in Figure
4. The median severity scores of the 5-5-5 exacerba-
tion grading scale in each group showed 13 in the AC
group, 32.5 in the AKC group, and 243 in the VKC
group. A statistically significant difference was found
among the groups (P < 0.001, Kruskal-Wallis test). In
addition, the distribution of this scale for the AC,
Exacerbation Grading Scale for ACD
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Fig. 1 A-1: Active giant papilae.“Active giant papilae” means a giant papilary proliferation (cobblestone appearance) that 
spreads in a hemispherical shape on the superior tarsal conjunctiva with mucous discharge. A-2: Gelatinous infiltrates of the 
limbus. Broad, thickened and gelatinous opacification is observed at the limbus. A-3: Exfoliative epithelial keratopathy. Exfolia
tive epithelial keratopathy is superficial punctate keratopathy with a mucous thread containing the fibrinous discharge, infiltrated 
inflammatory cels and deciduous epithelium. Clinical appearance is forming reticular and white opacification at the corneal 
surface. A-4: Shield ulcer. Shield ulcer is a horizontaly oval, shalow and nonvascularized ulcer of the cornea. A-5: Papilary pro
liferation at lower palpebral conjunctiva. The papilary proliferation at the lower palpebral conjunctiva is a clinical observation to 
be distinguished from the papilary proliferation at the upper palpebral conjunctiva. The velvety appearance of the papilary pro
liferation is observed in patients with severe atopic keratoconjunctivitis.
A-4 A-5
A-1 A-2 A-3
Table 2 Judging guidelines for 5-5-5 exacerbation grading scale for alergic conjunctivitis disease
Exacerbation grading scale
1-point-grade10-point-grade100-point-gradeGrade of clinical sign
Papilae at upper palpebral con-
junctiva
BlepharitisActive giant papilae † 
Clinical signs
Folicular lesion at lower palpe-
bral conjunctiva
Papilary proliferation with vel-
vety appearance
Gelatinous infiltrates of the 
limbus
Hyperemia of palpebral conjunc-
tiva
Horner-Trantas spotsExfoliative epithelial kerato-
pathy
Hyperemia of bulbal conjunctivaEdema of bulbal conjunctivaShield Ulcer
Lacrimal efusion ‡ Superficial punctate keratopa-
thy
Papilary proliferation at 
lower palpebral conjunctiva
1 point × number of positive 
signs
10 points × number of positive 
signs
100 points × number of 
positive signsScore
0-5 points0-50 points0-500 pointsRange
 † “Active giant papilae” means the giant papilary proliferation that spreads in hemispherical shape with mucous discharge, but mucous 
discharge is not essential. Giant papilae with flatness and poor inflammation findings are excluded.
 ‡ “Lacrimal efusion”refers to epiphora or tear meniscus increase caused by an eye iritation symptom.
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Fig. 2 B-1: blepharitis. B-2: papilary proliferation with velvety appearance. B-3: Horner-Trantas spots. B-4: edema of bulbal 
conjunctiva. B-5: superficial punctate keratopathy.
B-4 B-5
B-1 B-2 B-3
Fig. 3 C-1: papilae at upper palpebral conjunctiva. C-2: folicular lesion at lower palpebral conjunctiva. C-3: hyperemia of pal
pebral conjunctiva. C-4: hyperemia of bulbal conjunctiva. C-5: lacrimal efusion. “Lacrimal efusion” means epiphora or tear me
niscus increase caused by an eye iritation symptom.
C-4 C-5
C-1 C-2 C-3
Exacerbation Grading Scale for ACD
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Fig. 4 Results of severity score determined by 5-5-5 exac-
erbation grading scale in VKC, AKC and AC patients. The 
severity scores of each type of alergic conjunctivitis disease 
were significantly diferent among VKC, AKC and AC 
patients. (P < 0.001, Kruskal-Walis test). VKC, vernal kera-
toconjunctivitis; AKC, atopic keratoconjunctivitis; AC, aler-
gic conjunctivitis.
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Fig. 5 Distribution of the severity score in alergic conjunc
tivitis patients. The border value to distinguish moderate se
verity from mild severity was determined as 10 points. The 
border value to distinguish severe severity from moderate 
severity was determined as 30 points.
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Table 3 Criteria of severity classification in alergic conjunctivitis disease
VKCAKCAC　
More than two clinical observations 
classified in 100-point-grade are 
observed.
At least one of the clinical observa-
tion classified in 100-point-grade is 
observed.
More than three clinical observa-
tions classified in 10-point-grade 
are observed, and those in 100-
point-grade are absent.
Severe
Only one clinical observation classi-
fied in 100-point-grade is observed.
More than three clinical observa-
tions classified in 10-point-grade 
are observed, and those in 100-
point-grade are absent.
Less than two clinical observat-
ions classified in 10-point-grade 
are observed, and those in 100-
point-grade are absent.
Moderate
Clinical observation classified in 100-
point-grade is absent.
Less than two clinical observations 
classified in 10-point-grade are ob-
served, and those in 100-point-gra-
de are absent.
Clinical observation classified in 
10- or 100-point-grade is absent.
Mild
AC, alergic conjunctivitis; AKC, atopic keratoconjunctivitis; VKC, vernal keratoconjunctivitis.
AKC and VKC groups are shown as graphs in Figure
5, 6, and 7, respectively. The severity classes of each
group were divided into mild, moderate or severe, ac-
cording to the criteria shown in Table 3. The number
of patients in each severity group is shown in Figure
5, 6, and 7.
DISCUSSION
We set out to determine the practical usefulness of a
scoring system using the 5-5-5 exacerbation grading
scale for allergic conjunctivitis disease (ACD). This
study demonstrated that the use of the 5-5-5 exacer-
bation grading scale to assess clinical observations of
ACD using the clinical severity score is simple and
quick, and therefore suitable for follow-up examina-
tions. The simplicity of the grading method, judging
representative ACD findings as either present or ab-
sent, was reflected in the low inter-observer variabil-
ity. There have been reports on clinical scores of pa-
tients with ACD2,3,7 in which the severity of ACD and
the effects of antiallergic drugs were evaluated using
clinical scores. Clinical scores were used to deter-
mine a multi-point score for each representative ob-
servation of ACD. For each end point, ‘severe’ was
equivalent to 3 points, ‘moderate’ to 2 points and
‘mild’ to 1 point. However, the problem with such
clinical scores is that 1 point may represent a differ-
ent of severity for each observation category. How-
ever, using our method, the 3-graded clinical observa-
tions provide the best measure for current severity of
diseases in patients with ACD. An example of a 3-
graded evaluation is the Japanese coma scale, which
is used to evaluate comatose status using a 3-3-9 grad-
ing scale.11 A characteristic of this evaluation method
is that the score expresses clinical severity precisely
by giving high points for severe observations and low
points for mild observations. The 5-5-5 exacerbation
grading scale used in our study follows the same con-
Shoji J et al.
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Fig. 6 Distribution of the severity scores in atopic kerato
conjunctivitis patients. The border value to distinguish mod
erate severity from mild severity was determined as 30 
points. The border value to distinguish severe severity from 
moderate severity was determined as 100 points.
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Fig. 7 Distribution of the severity score in vernal kerato
conjunctivitis patients. The border value to distinguish mod
erate severity from mild severity was determined as 100 
points. The border value to distinguish severe severity from 
moderate severity was determined as 200 points.
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cept as this coma scale. According to our grading
scale, the observations found in patients with severe
VKC or AKC were classified as the “100-point-grade
group” where 1 end point was equivalent to 100
points. Similarly, the observations found in patients
with mild VKC or with severe AC were classified as
the “10-point-grade group”, where 1 end point was
equivalent to10 points. The observations found in pa-
tients with mild AC were classified as the “1-point-
grade group”, where 1 end point was equivalent to 1
point. Therefore, using this exacerbation grading
scale, the accumulation of severity scores could be
found in severe cases. It is obvious that as the condi-
tion of the patient improves the severity score de-
creases, to the point where the patient no longer ap-
pears for treatment, with the consequent absence of
further clinical findings.
In selecting the determinants for our grading scale,
clinical observations with high frequency were
adopted. General observations for VKC, giant papil-
lae, gelatinous proliferative lesion at the limbus, and
shield ulcer are noted.6,12,13 In addition, it has been
reported that the papillary proliferation often found in
the lower palpebral conjunctiva is crucial in AKC ob-
servation.14,15 Therefore, the determinants for the
100-point-grade group contain those observations
which develop in patients with severe VKC and AKC.
It has been reported that corneal plaque and fibrosis
of the palpebral conjunctiva are pathognomonic ob-
servations developing in patients with VKC and AKC.
It is rare that both were observed in the acute phase
of allergic inflammation as they are often present in
the healing stage, and therefore, cornea plaque and fi-
brosis of the palpebral conjunctiva were excluded in
this scale for the purpose of determining alterations
in severity. Trantas dots and papillary proliferation
with velvety appearance that are found in severe AC,
AKC and VKC, are included in the 10-points-grade
group. Furthermore, observations that were common
and nonspecific for ACD are included in the 1-point-
grade group. The 5 determinants of each grade cho-
sen in this manner are believed to be more useful ob-
servations in determining the severity of ACD in each
patient.
In our study, we measured the scores in patients
with VKC, AKC, and AC. As a result, the range of
clinical severity scores in each clinical type of ACD
was clarified and could be classified as severe, mod-
erate or mild. These classifications will help in select-
ing the most suitable medical therapy for patients
with ACD.
The 5-5-5 exacerbation grading scale is a useful
clinical tool for grading the severity of each type of
ACD, and may also be applied when evaluating the ef-
fects of medical treatment.
REFERENCES
1. Friedlaender MH. Conjunctivitis of allergic origin: clinical
presentation and differential diagnosis. Surv Ophthalmol
1993;38:105-14.
2. Nivenius E, Montan PG, Chryssanthou E, Jung K, van
Hage-Hamsten M, van der Ploeg I. No apparent associa-
tion between periocular and ocular microcolonization and
the degree of inflammation in patients with atopic kerato-
conjunctivitis. Clin Exp Allergy 2004;34:725-30.
3. Uchio E, Kimura R, Migita H, Kozawa M, Kadonosono K.
Demographic aspects of allergic ocular diseases and
evaluation of new criteria for clinical assessment of ocular
allergy. Graefes Arch Clin Exp Ophthalmol 2008;246:291-
6.
4. Montan PG, van Hage-Hamsten M. Eosinophil cationic
protein in tears in allergic conjunctivitis. Br J Ophthalmol
1996;80:556-60.
Exacerbation Grading Scale for ACD
Allergology International Vol 58, No4, 2009 www.jsaweb.jp 597
5. Calonge M, Herreras JM. Clinical grading of atopic kera-
toconjunctivitis. Curr Opin Allergy Clin Immunol 2007;7:
442-5.
6. Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical
grading of vernal keratoconjunctivitis. Curr Opin Allergy
Clin Immunol 2007;7:436-41.
7. Leonardi A, Borghesan F, Avarello A, Plebani M, Secchi
AG. Effect of lodoxamide and disodium cromoglycate on
tear eosinophil cationic protein in vernal keratoconjunc-
tivitis. Br J Ophthalmol 1997;81:23-6.
8. Bielory L. Allergic and immunologic disorders of the eye.
Part II: Ocular allergy. J Allergy Clin Immunol 2000;106:
1019-32.
9. Hogan MJ. Atopic keratoconjunctivitis. Trans Am Oph-
thalmol Soc 1952;50:265-81.
10. Foster CS, Calonge M. Atopic keratoconjunctivitis. Oph-
thalmology 1990;97:992-1000.
11. Ohta T. Phenomenological aspects of consciousness―its
disturbance in acute and chronic stage. Acta Neurochir
Suppl 2005;93:191-3.
12. Bonini S, Bonini S, Lambiase A et al. Vernal Keratocon-
junctivitis revisited. A case series of 195 patients with
long-term followup. Ophthalmology 2000;107:1157-63.
13. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye.
Clin Exp Immunol 2008;153(Suppl 1):17-21.
14. Hogan MJ. Atopic keratoconjunctivitis. Trans Am Oph-
thalmol Soc 1952;50:265-81.
15. Foster CS, Calonge M. Atopic keratoconjunctivitis. Oph-
thalmology 1990;97:992-1000.
